INTRODUCTION: Limited real-world evidence exists about the burden of atopic dermatitis (AD) in patients receiving systemic or non-systemic therapies in clinical practices. ESSENTIAL AD was an observational study that aimed to fill this information gap. METHODS: ESSENTIAL AD enrolled (September 2021-June 2022) adult patients with physician-confirmed AD that was routinely managed with systemic and non-systemic treatment in a real-world setting from 15 countries in Eastern Europe, the Middle East, and Africa. Primary outcome variables were Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and Dermatology Life Quality Index (DLQI) assessed during one office visit. RESULTS: A total of 799 enrolled patients fulfilled selection criteria and were included in the study. Patients mean (standard deviation [SD]) age was 36.3 (14.4) years, 457 (57.2%) were female, and the majority of patients were white (647 [81.0%]). Mean (SD) time since AD diagnosis was 17.6 (15.2) years (median 16.5; interquartile range [IQR] 3.3-26.8). The mean (SD) EASI, SCORAD, and DLQI total scores were 11.3 (11.3 [median 8.1; IQR 3.6-15.8]), 37.8 (17.9 [median 35.5; IQR 24.2-49.0]), and 10.6 (7.2 [median 10.0; IQR 5.0-15.0]), respectively. Patients receiving systemic treatment had significantly higher disease burden (mean [SD] EASI 13.3 [13.0]; median [IQR] 9.6 [3.9-17.9]) versus non-systemic treatment (mean [SD] 9.3 [8.7]; median [IQR] 6.8 [3.0-13.2]; P < 0.0001). Results were similar for SCORAD (39.9 [19.6] vs 35.6 [15.7]; median [IQR] 38.6 [24.7-53.1] vs 32.6 [23.9-44.6]; P = 0.0017), and DLQI total scores (11.4 [7.4] vs 9.9 [6.9]; median [IQR] 11.0 [5.0-16.0] vs 9.0 [5.0-14.0]; P = 0.0033, respectively). CONCLUSION: Patients with AD continue to have substantial disease burden despite treatment with systemic therapy, suggesting that a need for effective disease management remains, including effective therapies that improve psychological outcomes and reduce economic burden of AD, in Eastern Europe, the Middle East, and Africa.

Patients with atopic dermatitis often suffer from debilitating symptoms that impact their everyday lives. Although several treatment options are available, many patients continue to experience symptoms of disease. The ESSENTIAL AD study assessed burden of atopic dermatitis in patients receiving systemic and/or non-systemic therapies in real-life clinical practices across 15 countries in Eastern Europe, the Middle East, and Africa. The results of the study demonstrated that adult patients with atopic dermatitis continue to have substantial disease burden regardless of treatment with systemic therapy or non-systemic therapy. The findings suggest that optimal management of atopic dermatitis needs to be reassessed in Eastern Europe, the Middle East, and Africa, especially as new, more effective treatment options become available to patients.

AbbVie Biopharmaceuticals GmbH Dubai United Arab Emirates

AbbVie Inc North Chicago IL USA

AbbVie Lda Amadora Portugal

ACK Tokuda Hospital Sofia Sofia Bulgaria

Agrippa Ionescu Emergency Clinical Hospital Bucharest Romania

Clinic of Dermatology Tartu University Hospital Tartu Estonia

Department of Dermatology and Venereology Medical University Sofia Sofia Bulgaria

Department of Dermatology As'ad Al Hamad Dermatology Center Kuwait City Kuwait

Department of Dermatology Faculty of Medicine Cairo University Giza Egypt

Department of Dermatology Pediatric Dermatology and Dermatological Oncology Medical University of Lodz Lodz Poland

Department of Dermatology University of Tartu Tartu Estonia

Department of Dermatovenereology University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Czech Republic

Division of Dermatology Stellenbosch University Cape Town South Africa

Faculty of Medicine Menoufia University Menofia Egypt

Laboratory of Autoinflammatory Genetic and Rare Skin Disorders at the Department of Dermatology Pediatric Dermatology and Dermatological Oncology Medical University of Lodz Lodz Poland

State Research Center of Dermatovenereology and Cosmetology Moscow Russian Federation

Trakia University Stara Zagora Bulgaria

Zobrazit více v PubMed

Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30. doi: 10.1016/j.jid.2016.07.012. PubMed DOI

Kapur S, Watson W, Carr S. Atopic dermatitis. Clin Immunol. 2018;14(Suppl 2):52. PubMed PMC

Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218–1233. doi: 10.1016/j.jaad.2014.08.038. PubMed DOI PMC

Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340–35. PubMed

Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888. PubMed DOI

Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903–912. doi: 10.1001/jamadermatol.2018.1572. PubMed DOI PMC

de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–1036. doi: 10.1111/jdv.16003. PubMed DOI PMC

Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290–300. doi: 10.1111/1346-8138.14787. PubMed DOI PMC

Han Y, Woo YR, Cho SH, Lee JD, Kim HS. Itch and Janus kinase inhibitors. Acta Derm Venereol. 2023;15(103):869. PubMed PMC

Al Hammadi A, Pakran J, Farghaly M, et al. Healthcare resource utilization and direct cost of patients with atopic dermatitis in Dubai, United Arab Emirates: a retrospective cohort study. Dermatol Ther (Heidelb) 2022;19:1–25. PubMed

Elezbawy B, Fasseeh AN, Fouly E, et al. Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa Region. Dermatol Ther (Heidelb) 2023;13(1):131–146. doi: 10.1007/s13555-022-00857-0. PubMed DOI PMC